Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Istaroxime

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Windtree Secures Istaroxime Patent Allowance For Acute Heart Failure
    Windtree Secures Istaroxime Patent Allowance For Acute Heart Failure

    04 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/04/3036439/0/en/Windtree-Announces-Istaroxime-Notice-of-Allowance-from-the-U-S-Patent-and-Trademark-Office-for-Acute-Heart-Failure.html

    GLOBENEWSWIRE
    04 Mar 2025
    Share Share
    Windtree To Present Istaroxime Data At Heart Failure Conference
    Windtree To Present Istaroxime Data At Heart Failure Conference

    12 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/12/3024995/0/en/Windtree-Announces-Special-Late-Breaking-Clinical-Science-Abstract-Presentation-on-Istaroxime-at-the-Technology-and-Heart-Failure-Therapeutics-Conference.html

    GLOBENEWSWIRE
    12 Feb 2025
    Share Share
    Windtree Files New Istaroxime Patent for Myocardial Arrhythmia
    Windtree Files New Istaroxime Patent for Myocardial Arrhythmia

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993691/0/en/Windtree-Announces-New-Istaroxime-Patent-Filing-for-Preventing-or-Reducing-the-Risk-of-Acute-Myocardial-Arrhythmia.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Windtree Partners for Potential Strategic Deal in Cardiogenic Shock
    Windtree Partners for Potential Strategic Deal in Cardiogenic Shock

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991425/0/en/Windtree-Announces-Partnership-with-New-Growth-Advisors-to-Leverage-Positive-Phase-2-Istaroxime-Study-in-Cardiogenic-Shock-for-a-Potential-Strategic-Transaction.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971647/0/en/Windtree-Therapeutics-Initiates-SEISMiC-C-Study-of-Istaroxime-in-SCAI-Stage-C-Cardiogenic-Shock-for-Planned-Completion-of-Phase-2b-and-Transition-to-Phase-3.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Windtree Announces Publication Of Istaroxime Phase 2b Design
    Windtree Announces Publication Of Istaroxime Phase 2b Design

    09 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/09/2960460/0/en/Windtree-Announces-Publication-of-Positive-Istaroxime-Phase-2b-Study-Trial-Design.html

    GLOBENEWSWIRE
    09 Oct 2024
    Share Share